Kari B. Wisinski, MD, associate professor (CHS), Hematology, Medical Oncology and Palliative Care, has received $1M over 24-30 months from the Advancing Science Through Pfizer-Investigator Research Exchange (ASPIRE) Breast Cancer Research Program for a proposal entitled, "Phase 2 trial with safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive HER2 negative breast cancers." 

This trial will be run through the Big Ten Cancer Research Consortium (CRC).

For this trial, Dr. Wisinski is working with Dr. Sneha Phadke of the University of Iowa Holden Cancer Center. The study is investigating the combination of two targeted agents for metastatic triple negative breast cancer.  

Dr. Wisinski was recently named to the steering committee of the Big Ten CRC.

Resources:

• "Pfizer to award more than $3 million in grants to further breast cancer research," Pfizer, October 4, 2018